| Optimizing hydroxychloroquine dosing for patients with COVID‐19: an integrative modeling approach for effective drug repurposing M Garcia‐Cremades, BP Solans, E Hughes, JP Ernest, E Wallender, ... Clinical Pharmacology & Therapeutics 108 (2), 253-263, 2020 | 129 | 2020 |
| Development of new tuberculosis drugs: translation to regimen composition for drug-sensitive and multidrug-resistant tuberculosis JP Ernest, N Strydom, Q Wang, N Zhang, E Nuermberger, V Dartois, ... Annual review of pharmacology and toxicology 61, 495-516, 2021 | 33 | 2021 |
| Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders B Yi, A Jahangir, AK Evans, D Briggs, K Ravina, J Ernest, AB Farimani, ... PLoS One 12 (7), e0180319, 2017 | 22 | 2017 |
| Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis JP Ernest, J Sarathy, N Wang, F Kaya, MD Zimmerman, N Strydom, ... Antimicrobial agents and chemotherapy 65 (10), 10.1128/aac. 00506-21, 2021 | 15 | 2021 |
| A rabbit model to study antibiotic penetration at the site of infection for nontuberculous mycobacterial lung disease: macrolide case study F Kaya, JP Ernest, K LoMauro, M Gengenbacher, A Madani, WW Aragaw, ... Antimicrobial agents and chemotherapy 66 (3), e02212-21, 2022 | 14 | 2022 |
| Pharmacometrics in tuberculosis: progress and opportunities JJ Wilkins, EM Svensson, JP Ernest, RM Savic, USH Simonsson, ... International Journal of Antimicrobial Agents 60 (3), 106620, 2022 | 7 | 2022 |
| Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modeling study KK Radtke, JP Ernest, N Zhang, NC Ammerman, E Nuermberger, ... Antimicrobial agents and chemotherapy 65 (12), 10.1128/aac. 01705-21, 2021 | 7 | 2021 |
| Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing M Garcia-Cremades, BP Solans, E Hughes, JP Ernest, E Wallender, ... Clin Pharmacol Ther. https://doi. org/10.1002/cpt, 1856 | 6 | 1856 |
| Lung microenvironments harbor Mycobacterium tuberculosis phenotypes with distinct treatment responses ND Walter, JP Ernest, C Dide-Agossou, AA Bauman, ME Ramey, ... Antimicrobial Agents and Chemotherapy 67 (9), e00284-23, 2023 | 4 | 2023 |
| Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs JP Ernest, JJN Goh, N Strydom, Q Wang, RC van Wijk, N Zhang, ... European Respiratory Journal 62 (2), 2023 | 1 | 2023 |
| LIMITED PENETRATION AND EFFICACY OF AMINOGLYCOSIDES IN LESIONS OF TUBERCULOSIS: A TRANSLATIONAL SITE-OF-ACTION PKPD MODELING STUDY. J Ernest, N Strydom, J Sarathy, M Zimmerman, V Dartois, R Savic CLINICAL PHARMACOLOGY & THERAPEUTICS 109, S28-S28, 2021 | 1 | 2021 |
| PREDICTING THE EARLY BACTERICIDAL ACTIVITY (EBA) OF TUBERCULOSIS (TB) DRUGS FOR THE PHASE IIA FIRST-IN-PATIENTS STUDIES. N Zhang, N Strydom, Q Wang, J Ernest, E Nuermberger, R Savic CLINICAL PHARMACOLOGY & THERAPEUTICS 107, S83-S83, 2020 | 1 | 2020 |
| It's That Time of Year-Give Yourself the Gift of SCIENCE! J Ernest CLINICAL PHARMACOLOGY & THERAPEUTICS 114 (6), 1161-1161, 2023 | | 2023 |
| Translating Nonclinical Findings to Prioritize Sterilizing Multi-Drug Regimens for the Treatment of Tuberculosis J Ernest University of California, San Francisco, 2022 | | 2022 |
| Response to “Quantitative Clinical Pharmacology INPUT to SARS‐CoV‐2 Therapeutics Should be Based on Robust Data” M Garcia‐Cremades, BP Solans, E Hughes, JP Ernest, E Wallender, ... Clinical pharmacology and therapeutics 108 (2), 189, 2020 | | 2020 |
